Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07222696

Pilot Randomized Trial of Health Coaching for People With Rheumatoid Arthritis to Improve Mental Well-Being

Led by Weill Medical College of Cornell University · Updated on 2026-01-22

250

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

W

Weill Medical College of Cornell University

Lead Sponsor

B

Bristol-Myers Squibb

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to find out if peer coaching can lower anxiety and depression in adults diagnosed with Rheumatoid Arthritis (RA). It compares the effect of peer coaching, delivered by individuals who also have RA, to coaching from people without RA who discuss general health topics. The study focuses on whether anxiety and depression improve six months after the coaching sessions. Participants will be randomly assigned to one of two groups. One group receives nine weekly telephone sessions with a peer coach who uses techniques from cognitive behavioral therapy (CBT), mindfulness, and exercise to address chronic pain and related issues. The other group receives nine telephone sessions with a coach who does not have RA and covers general health topics like nutrition and cancer awareness without using CBT or mindfulness. Sessions occur over 9 to 12 weeks, and data is collected multiple times during and after the intervention. Participants will complete surveys before starting, midway through, and at several timepoints after the sessions, including 3 weeks, 6 months, 12 months, and 24 months post-intervention. Researchers will measure changes in anxiety and depression using validated tools (PHQ-8 and GAD-7). Other assessments include pain interference, sleep disturbance, physical function, social isolation, stress, loneliness, and quality of life. The study monitors these outcomes to understand the impact of coaching on mental well-being in people with RA.

CONDITIONS

Brief Title

Healthier: Health Coaching for People With Rheumatoid Arthritis to Improve Mental Well-Being

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or Female older than 18 years of age
  • Diagnosed with Rheumatoid Arthritis by a rheumatologist and currently taking a Disease-Modifying Anti-rheumatic drug
  • Have high levels of depression (PHQ-8 scores 10 to 20) or high levels of anxiety (GAD-7 scores above 10)
  • Speaks English or Spanish
  • Has access to the internet, a computer, and/or a smartphone
  • Lives in any state of the US, including Puerto Rico
  • Willing to work with a peer coach or a coach
Not Eligible

You will not qualify if you...

  • Has a rheumatic disease other than Rheumatoid Arthritis (e.g., psoriatic arthritis, gout, lupus)
  • Is a nursing home resident
  • Has a history of dementia or severe cognitive decline
  • Is currently bedbound
  • Has severe depression (PHQ-8 scores above 20)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 screening and enrollment visit (telephone or online)

Treatment

Duration - 9 to 12 weeks

Participants receive 9 telephone-delivered health coaching sessions over 9 to 12 weeks, either from a peer coach with rheumatoid arthritis or a coach with another chronic condition.

9 telephone sessions

Follow-up

Duration - Up to 24 months post-intervention

Participants are followed up for ongoing assessment of mental well-being and other outcomes for up to 24 months after completing the coaching intervention.

Assessments at 3 weeks, 6 months, 12 months, and 24 months post-intervention

Trial Site Locations

Total: 1 location

1

Weill Cornell Medical College

New York, New York, United States, 10065

Actively Recruiting

Loading map...

Research Team

I

Iris Navarro-Millán, MD, MPH

S

Sarah Young, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Similar Trials

A Phase I, Open-Label Study of CLN-978 in Patients With Trea...

Rheumatoid Arthritis (RA

Actively Recruiting

3 locations

An Open-label Phase 2a Study to Evaluate the Safety and Effi...

Refractory Rheumatoid Arthritis (RA)

Actively Recruiting

52 locations

An Alternative Assessment in Patients with Rheumatoid Arthri...

Rheumatoid Arthritis (RA

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Frequency of comorbid insomnia, pain, and depression in older adults with osteoarthritis: predictors of enrollment in a randomized treatment trial.

Susan M McCurry, Michael Von Korff, Michael V Vitiello...

https://pubmed.ncbi.nlm.nih.gov/21999972

Screening instruments for a population of older adults: The 10-item Kessler Psychological Distress Scale (K10) and the 7-item Generalized Anxiety Disorder Scale (GAD-7).

Helen-Maria Vasiliadis, Veronica Chudzinski, Samantha Gontijo-Guerra...

https://pubmed.ncbi.nlm.nih.gov/25956759

Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7).

Anne Toussaint, Paul Hüsing, Antje Gumz...

https://pubmed.ncbi.nlm.nih.gov/32090765

Effective dose 50 method as the minimal clinically important difference: Evidence from depression trials.

Clarissa Bauer-Staeb, Daphne-Zacharenia Kounali, Nicky J Welton...

https://pubmed.ncbi.nlm.nih.gov/33892086

Practice Facilitation and Peer Coaching for Uncontrolled Hypertension Among Black Individuals: A Randomized Clinical Trial.

Monika M Safford, Doyle M Cummings, Jacqueline R Halladay...

https://pubmed.ncbi.nlm.nih.gov/38497987